Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

For more information on Age-Related Macular Degeneration go to the NHS website. If you've had a diagnosis, in addition to ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Collaboration between TLI and AMDF underscores a shared commitment to making a meaningful difference in the lives of those affected by AMD. Together, TLI and AMDF are dedicated to advancing awareness, ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...